Abstract: A positioning apparatus includes a mounting plate, a driving assembly, and two first position assemblies. The mounting plate defines a first guiding groove. The driving assembly is mounted on the mounting plate and includes a driver, and a transfer rod coupled to the driver. The first pivoting assembly includes a first coupling rod and a second coupling rod. The first coupling rod is movably received in the first guiding groove and pivotably coupled to the transfer rod. The second coupling rod is movably received in the first guiding groove and pivotably coupled to the transfer rod. The first position assemblies are respectively pivotably coupled to the first coupling rod and the second coupling rod.

Abstract: A film-applying machine includes a bracket, a mechanical arm, an application apparatus, and a storage apparatus. The storage apparatus includes a storage mechanism, a driving mechanism, and a first rolling mechanism. The storage mechanism includes a supporting frame mounted to the bracket, and a storage assembly adjustably coupled to the supporting frame. The driving mechanism includes a supporting member and a driving assembly. The supporting member couples with the supporting frame. The driving assembly includes a driving member coupled to the supporting member and a first transmission belt coupled to the driving member. The first rolling mechanism includes a pressing plate and a plurality of rollers. An end of the pressing plate couples with the first transmission belt, and another end is coupled to the supporting frame. The rollers are rotatably mounted on the pressing plate.

Abstract: A set of nonnegative lighting basis images representing a scene illuminated by a set of stationary light sources is recovered from a set of input images of the scene that were acquired by a stationary camera. Each image is illuminated by a combination of the light sources, and at least two images in the set are illuminated by different combinations. The set of input images is decomposed into the nonnegative lighting basis images and a set of indicator coefficients, wherein each lighting basis image corresponds to an appearance of the scene illuminated by one of the light sources, and wherein each indicator coefficient indicates a contribution of one of the light sources to one of the input images.

Abstract: Three-dimensional (3D) geometric boundaries are detected in images of a scene that undergoes varying lighting conditions caused by light sources in different positions, from a set of input images of the scene illuminated by at least two different lighting conditions. The images are aligned, e.g., acquired by a stationary camera, so that pixels at the same location in all of the input images correspond to the same point in the scene. For each location, a patch of corresponding pixels centered at the location is extracted from each input image. For each location, a confidence value that there is a 3D geometric boundary at the location is determined.

Abstract: Briefly, embodiments of methods or systems for a display signal buffer are disclosed.

Abstract: An apparatus configured for stripping a release paper from a workpiece, including a base defining a through hole, a pushing mechanism mounted on the base adjacent to the through hole; and a stripping mechanism mounted on the base. The stripping mechanism includes a bracket mounted on the base, a driving member mounted on the base away from the pushing mechanism and abutting the through hole, a pushing member connected to the driving member towards the through hole, and an suction assembly including an suction driving member fixedly-connected to the bracket and an suction member connected to the suction driving member. The driving member enables the pushing member to extend into the through hole for clamping the release paper between the pushing member and the pushing mechanism, and the suction member is capacity of sucking and moving the workpiece.

Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

Abstract: Disclosed is a method for establishing a CoMP cooperating set in coordinated multi-point communication, the method comprising the steps of: triggering and starting a coordinated multi-point communication process; according to channel state information of all cells in a measurement cell set measured by a UE, determining a candidate CoMP cooperating set; sending a CoMP cooperating set establishment request to eNodeBs of the cooperating cells in the determined candidate CoMP cooperating set; the eNodeBs being of the cooperating cell and receiving the CoMP cooperating set establishment request responding to the CoMP cooperating set establishment request to the eNodeB of the serving cell of the UE, and sending a CoMP cooperating set establishment response to the eNodeB of the serving cell of the UE; the eNodeB of the serving cell of the UE determining a CoMP cooperating set of the UE according to information of the CoMP cooperating set establishment response; and according to a coordinated multi-point communicatio

Abstract: A host controller for a bus is disclosed. The host controller includes a plurality of functional modules interconnected to manage transfer of data between a host bus and a root hub configured to communicate with one or more USB device endpoints on the bus. The plurality of functional modules comprises a DMA engine to transfer one or more data payloads between the host bus and the root hub, a transfer manager configured to determine what control data and/or data payloads should be transferred, and a scheduler to schedule actions performed by the transfer manager. A plurality of control memories, each associated with one or more of the functional modules, store state and/or data information fields accessible by its one or more associated functional modules. The plurality of control memories are distinct and independently accessible from one another.

Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, autoimmune and cardiovascular diseases.

Abstract: Tetrahydrocarboline compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.

Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

Abstract: Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, phospholipid kinases, G-protein coupled receptors, and phosphatases.

Abstract: New pyrrole based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, autoimmune and cardiovascular diseases.

Abstract: Novel immune potentiators, novel vaccine adjuvants, novel compounds and pharmaceutical compositions, as well as novel methods for treating viral infections, including HCV, by administering the compounds and compositions, and novel methods for modulating the immune response by administering the compounds and/or compositions.

Abstract: Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.

Abstract: Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of the desmethyl-vancomycin scaffold, in particular, acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this scaffolds to certain substituted amides. In addition, compounds of the invention include desmethyl-vancomycin scaffolds on which the acid moiety on the macrocyclic ring is converted to certain substituted amides and the amino substituent on the amino-substituted sugar moiety is alkylated with certain alkyl groups. Also provided are methods for synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections.